Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ranbaxy Laboratories has started shifting production of atorvastatin from its current Ohm, New Jersey, US, facility to its new manufacturing facility in Mohali,Punjab, India.
Subscribe to our email newsletter
Atorvastatin, a generic version of Pfizer’s Lipitor, is used to lower blood cholesterol levels.
In addition, Ranbaxy has received the US Food and Drug Administration approval to market its generic version of Novartis’ $6bn hypertension drug ,Diovan, from the Mohali plant.
Ranbaxy Laboratories CEO Arun Sawhney was quoted by The Economic Times as saying that, "There are more approvals coming through and will come through from Mohali facility because quite a bit of our regulatory submissions in the recent times have gone from Mohali."
Ranbaxy said it will manufacture tablets, capsules and dry syrups in Mohali to mainly cater to regulated markets such as the US, EU and Japan.